What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Her scientific interests lie mostly in Internal medicine, Lung cancer, Oncology, Chemotherapy and Surgery.
Her Internal medicine study focuses mostly on Carcinoma, Clinical endpoint, Carboplatin, Pemetrexed and Survival rate.
She has researched Carcinoma in several fields, including Stage, Radiation therapy and Survival analysis.
The Lung cancer study combines topics in areas such as Cancer, Chemotherapy regimen, Docetaxel, Epidermal growth factor receptor and Placebo.
Her studies in Oncology integrate themes in fields like Pembrolizumab and Hazard ratio.
Her Surgery research includes elements of Gastroenterology, Respiratory disease and Adverse effect.
Her most cited work include:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † (1452 citations)
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (1030 citations)
What are the main themes of her work throughout her whole career to date?
Silvia Novello mostly deals with Internal medicine, Oncology, Lung cancer, Chemotherapy and Non small cell.
Her Internal medicine study typically links adjacent topics like Surgery.
Her work in Surgery addresses subjects such as Gastroenterology, which are connected to disciplines such as Neutropenia.
Vinorelbine is closely connected to Gemcitabine in her research, which is encompassed under the umbrella topic of Oncology.
In her study, which falls under the umbrella issue of Lung cancer, Tyrosine kinase is strongly linked to Cancer research.
Her study connects Clinical endpoint and Chemotherapy.
She most often published in these fields:
- Internal medicine (69.27%)
- Oncology (60.27%)
- Lung cancer (52.80%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (69.27%)
- Oncology (60.27%)
- Lung cancer (52.80%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Lung cancer, Non small cell and Cancer research.
Her work investigates the relationship between Internal medicine and topics such as Placebo that intersect with problems in Gastroenterology.
Her Oncology study integrates concerns from other disciplines, such as Docetaxel and Immunotherapy.
The study incorporates disciplines such as Clinical trial, Disease and Epidermal growth factor receptor in addition to Lung cancer.
Silvia Novello interconnects Stage iv and Immune checkpoint inhibitors in the investigation of issues within Non small cell.
Silvia Novello has included themes like Carboplatin and Carcinoma in her Pembrolizumab study.
Between 2017 and 2021, her most popular works were:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (1030 citations)
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (178 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Silvia Novello focuses on Internal medicine, Lung cancer, Oncology, Pembrolizumab and Clinical trial.
Internal medicine is closely attributed to Placebo in her study.
Her Placebo research is multidisciplinary, incorporating perspectives in Gastroenterology, Clinical endpoint and Performance status.
Silvia Novello combines subjects such as Survival rate and Randomized controlled trial with her study of Lung cancer.
Her Oncology research integrates issues from Stage iv, Carcinoma, Docetaxel and Adenocarcinoma.
Her Clinical trial study incorporates themes from Biomarker and Radiology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
